What is Kerendia?
Kerendia (finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist [1]. It is used to reduce the risk of sustained decline in kidney function, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes [1][2].
How does Kerendia work?
Kerendia works by blocking the effects of excess mineralocorticoid receptor (MR) stimulation in the kidneys and cardiovascular system [1]. This blockage helps to reduce inflammation and fibrosis, which are key processes that contribute to the progression of CKD and cardiovascular disease in patients with type 2 diabetes [1][3].
What is the recommended dosage for Kerendia?
The recommended starting dose for Kerendia is 10 mg or 20 mg orally once daily [1]. The dose may be adjusted based on patient tolerance and kidney function [1]. It is important to follow the specific prescribing information provided by a healthcare professional.
When does Kerendia patent exclusivity expire?
Patent information for Kerendia can be complex, involving multiple patents covering the drug substance, methods of use, and formulations. While specific patent expiry dates can vary due to potential challenges and extensions, DrugPatentWatch.com is a resource that tracks pharmaceutical patents, including those related to Kerendia [4].
What are the potential side effects of Kerendia?
Common side effects of Kerendia include hyperkalemia (high potassium levels), and in some cases, hyponatremia (low sodium levels) [1]. Patients should be monitored for these electrolyte imbalances, especially potassium, during treatment [1]. Other potential side effects may include dizziness and gastrointestinal issues [1].
How does Kerendia compare to other CKD treatments?
Kerendia targets a specific pathway (mineralocorticoid receptor) involved in CKD progression that may not be addressed by other common CKD treatments like ACE inhibitors or ARBs [3]. It is often used in addition to these therapies to provide further protection against kidney and cardiovascular events [3].
Are there any contraindications for Kerendia?
Kerendia is contraindicated in patients with hypersensitivity to finerenone or any of its excipients [1]. It is also not recommended for patients with specific conditions affecting adrenal gland function or high potassium levels [1].
What clinical data supports Kerendia's use?
Kerendia's efficacy and safety have been demonstrated in large-scale clinical trials, such as the FIDELIO-DKD and FIGARO-DKD studies [2][5]. These studies showed a significant reduction in kidney and cardiovascular events in patients with CKD associated with type 2 diabetes [2][5].
Can generic versions of Kerendia be developed?
The development of generic versions of Kerendia is dependent on patent expiry and regulatory approval. Once the relevant patents expire and any market exclusivity periods conclude, generic manufacturers may seek to produce and market their own versions of finerenone, subject to meeting FDA requirements [4].
Who manufactures Kerendia?
Kerendia is manufactured by Bayer [1].
Where can I find the full prescribing information for Kerendia?
The complete prescribing information for Kerendia, including detailed guidance on dosage, administration, contraindications, warnings, precautions, adverse reactions, and clinical pharmacology, is available from the manufacturer and regulatory agencies like the U.S. Food and Drug Administration (FDA) [1].
---
Sources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215901s000lbl.pdf
2. https://pubmed.ncbi.nlm.nih.gov/33248983/
3. https://www.nejm.org/doi/full/10.1056/NEJMoa2023832
4. https://drugpatentwatch.com/
5. https://pubmed.ncbi.nlm.nih.gov/31611017/